ExonHit presents promising first patient results for EHT 0202, its Alzheimer’s candidate drug
15-Sep-2009
- France
Most read news
Topics
Organizations
ExonHit Therapeutics
ALIZE
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
VASTox provides grant to support Duchenne Muscular Dystrophy patient registry
Go to page
Transition Therapeutics Acquires All Remaining Shares of NeuroMedix Inc.
Go to page
Ablynx initiates Phase I/II trial for ALX-0061 (Anti-IL-6R) in patients with rheumatoid arthritis
Go to page
Sanofi-aventis Canada appoints Hugh O'Neill as President and CEO
Go to page